RHO家族GTP酶生物信息学分析确定RAC1药理抑制作为肝细胞癌新治疗策略
该研究通过公共数据集分析发现RAC1在肝细胞癌中表达上调、与患者生存期差相关并富集促癌转录程序,在体外和体内评估RAC1抑制剂1D-142的抗肿瘤及抗纤维化作用,结果显示1D-142可诱导凋亡和细胞周期阻滞、减少小鼠模型肿瘤生长和肝内转移并减轻肝纤维化。
要点
- RAC1在肝细胞癌中表达上调,与患者生存期差相关并富集促癌转录程序。
- RAC1抑制剂1D-142在体外诱导肝癌细胞凋亡和细胞周期阻滞。
- 1D-142在小鼠模型中减少肿瘤生长和肝内转移,并减轻肝纤维化。
核心结论
- 对肝细胞癌数据集的生物信息学分析可将RAC1确定为肝细胞癌的新治疗靶点。
- 1D-142靶向抑制RAC1在纤维化肝脏中建立的高增殖性肝细胞癌中产生强效抗肿瘤作用。
研究设计与样本
- 研究使用公共数据集分析肝细胞癌中RHO家族GTP酶的表达失调、临床预后及转录程序。
- 在体外和体内研究RAC1抑制剂对肝细胞癌的治疗潜力。
- 使用RNA-Seq分析及其与三个不同肝细胞癌数据集的相关性来刻画RAC1抑制的潜在机制。
- 评估RAC1抑制对肝纤维化的治疗效果。
主要发现
- 在RHO家族GTP酶中观察到RAC1表达上调,与患者生存期差相关,并与促癌转录程序强相关。
- 在研究的系列新型RAC1抑制剂中,1D-142能够诱导肝细胞癌细胞凋亡和细胞周期阻滞,在高增殖细胞中显示更强作用。
- 在肝细胞癌中,1D-142抑制RAC1可部分逆转RAC1相关致癌转录程序。
- RAC1抑制剂1D-142在肝细胞癌小鼠模型中强烈减少肿瘤生长和肝内转移。
- 1D-142减少肝星状细胞活化并在体内发挥抗纤维化作用。
关键数值与推荐
- 在RHO家族GTP酶中观察到RAC1表达上调,与患者生存期差相关,并与促癌转录程序强相关。
- 在研究的系列新型RAC1抑制剂中,1D-142能够诱导肝细胞癌细胞凋亡和细胞周期阻滞,在高增殖细胞中显示更强作用。
- 1D-142抑制RAC1可部分逆转RAC1相关致癌转录程序。
- 1D-142在肝细胞癌小鼠模型中强烈减少肿瘤生长和肝内转移。
- 1D-142减少肝星状细胞活化并在体内发挥抗纤维化作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The RHO family of GTPases, particularly RAC1, has been linked with hepatocarcinogenesis, suggesting that their inhibition might be a rational therapeutic approach. We aimed to identify and target deregulated RHO family members in human hepatocellular carcinoma (HCC). DESIGN: We studied expression deregulation, clinical prognosis and transcription programmes relevant to HCC using public datasets. The therapeutic potential of RAC1 inhibitors in HCC was study in vitro and in vivo. RNA-Seq analysis and their correlation with the three different HCC datasets were used to characterise the underlying mechanism on RAC1 inhibition. The therapeutic effect of RAC1 inhibition on liver fibrosis was evaluated. RESULTS: Among the RHO family of GTPases we observed that RAC1 is upregulated, correlates with poor patient survival, and is strongly linked with a prooncogenic transcriptional programme. From a panel of novel RAC1 inhibitors studied, 1D-142 was able to induce apoptosis and cell cycle arrest in HCC cells, displaying a stronger effect in highly proliferative cells. Partial rescue of the RAC1-related oncogenic transcriptional programme was obtained on RAC1 inhibition by 1D-142 in HCC. Most importantly, the RAC1 inhibitor 1D-142 strongly reduce tumour growth and intrahepatic metastasis in HCC mice models. Additionally, 1D-142 decreases hepatic stellate cell activation and exerts an anti-fibrotic effect in vivo. CONCLUSIONS: The bioinformatics analysis of the HCC datasets, allows identifying RAC1 as a new therapeutic target for HCC. The targeted inhibition of RAC1 by 1D-142 resulted in a potent antitumoural effect in highly proliferative HCC established in fibrotic livers.
引用
- Bayo J, Fiore EJ, Dominguez LM, et al. Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma. Gut. 2020. PMID: 33106353. doi:10.1136/gutjnl-2020-321454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。